The Company continues to advance proprietary diagnostic technologies and has established multi-omics diagnostic technology platforms encompassing protein biomarkers, GlyExo-Capture®, DNA methylation, and other technologies. Its innovative technology incubation platform, the Institute of Future Technology, has expanded into cutting-edge fields such as nucleic acid therapeutics, antibody therapeutics, and health and wellness. SGC001, a first-in-class antibody therapeutic for acute myocardial infarction (AMI), has received FDA Fast Track designation and has been approved for clinical trials in both China and the United States. It is currently undergoing a Phase II multicenter clinical trial in China.